Premium
SLC7A7 genomic structure and novel variants in three Japanese lysinuric protein intolerance families
Author(s) -
Noguchi Atsuko,
Shoji Yutaka,
Koizumi Akio,
Takahashi Tsutomu,
Shoji Yasuko,
Matsumori Mika,
Kayo Tsuyoshi,
Ohata Tomoaki,
Wada Yasuhiko,
Yoshimura Ihoko,
Maisawa Shunichi,
Konishi Mineo,
Takasago Yuhei,
Takada Goro
Publication year - 2000
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/(sici)1098-1004(200004)15:4<367::aid-humu9>3.0.co;2-c
Subject(s) - biology , intron , exon , genomic dna , genetics , microbiology and biotechnology , rna splicing , gene , nonsense mutation , untranslated region , complementary dna , mutation , missense mutation , rna
Lysinuric protein intolerance (LPI) is a rare inherited disease caused by defective transport of the dibasic amino acids at the basolateral membranes of epithelial cells in the renal tubules and small intestine. The metabolic defect leads to brain dysfunction caused by hyperammonemia with a functional impairment of the urea cycle. Recently, mutations in the human SLC7A7 cDNA coding for y + LAT‐1, which express dibasic amino acid transport activity, were reported to be responsible for LPI. In the present study, we examined the genomic structure of SLC7A7 by DNA sequencing of PCR products, and determined that the gene had 11 exons and 10 introns spanning about 18 kb of genomic DNA. We also identified an alternative RNA splicing at the 5′ untranslated region of the SLC7A7 mRNA in human peripheral blood leukocytes, cultured lymphoblasts, and fibroblasts. As a result of mutational analysis of SLC7A7 in three Japanese LPI families, we found a nonsense mutation (R410X), a splicing mutation(911+1G>A) in intron 4, and four silent polymorphisms (201C/T, 445A/G, 784C/T, 946T/C). Identification of the genomic structure of SLC7A7 may provide a molecular basis for a genetic survey for LPI. Hum Mutat 15:367–372, 2000. © 2000 Wiley‐Liss, Inc.